WO2003005962A2 - Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate - Google Patents

Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate Download PDF

Info

Publication number
WO2003005962A2
WO2003005962A2 PCT/US2002/022039 US0222039W WO03005962A2 WO 2003005962 A2 WO2003005962 A2 WO 2003005962A2 US 0222039 W US0222039 W US 0222039W WO 03005962 A2 WO03005962 A2 WO 03005962A2
Authority
WO
WIPO (PCT)
Prior art keywords
methylphenidate
threo
treatment
patient
oncological condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/022039
Other languages
English (en)
French (fr)
Other versions
WO2003005962A3 (en
Inventor
Jerome B. Zeldis
Herbert Faleck
Vikram Khetani
Andrew L. Zeitlin
Maghsoud M. Dariani
David I. Stirling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Priority to KR10-2004-7000312A priority Critical patent/KR20040029360A/ko
Priority to MXPA04000249A priority patent/MXPA04000249A/es
Priority to JP2003511771A priority patent/JP2005520780A/ja
Priority to CA2453510A priority patent/CA2453510C/en
Priority to EP02748129A priority patent/EP1411943A4/en
Priority to IL15931302A priority patent/IL159313A0/xx
Priority to AU2002318302A priority patent/AU2002318302B2/en
Priority to NZ530211A priority patent/NZ530211A/en
Publication of WO2003005962A2 publication Critical patent/WO2003005962A2/en
Publication of WO2003005962A3 publication Critical patent/WO2003005962A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures

Definitions

  • the oncological condition is a cancer selected from the group consisting of all malginant conditions, inclduing both solid tumors and nonsolid tumors. In some preferred embodiments, the oncological condition is a solid tumor.
  • D-threo methylphenidate will be particularly useful in treating patients affected by fatigue, neurobehavioral slowing, and other cognitive defects ('cognitive side effects") that are due to cancer, and that are exacerbated by the administration of treatments for cancer such as chemotherapy, radiation therapy, bone marrow transplants, stem cell transplants and administration of medication to control pain.
  • cognitive defects include but are not limited to neurobehavioral slowing, sedation, diminished executive function, decreased cognitive function, major depressive disorder and impaired quality of life.
  • the D-threo methylphenidate substantially free of L- threo methylphenidate and of erythro methylphenidates as described herein can be taken up in pharmaceutically acceptable carriers, such as, for example, solutions, suspensions, tablets, capsules, ointments, elixirs and injectable compositions.
  • Pharmaceutical preparations generally can contain from about 1 % to about 90% by weight of active ingredient. Preparations which are in single dose form, "unit dosage form", preferably contain from about 20 % to about 90 % active ingredient.
  • MMSE Mini-Mental State Exam
  • Attention and concentration can be evaluated via the Trial Making Test-Part A (See, for example, Reitan, R.M.: Validity of the Trail Making Test as an indicator of organic brain damage. Perceptual Motor Skills 8:271-276, 1958), and the Digit Span, Forward and Backward test (see, for example, Wechsler D. Wechsler Adult Intelligence Scale-Revised Manual. New York; Psychological Corporation, 1981)).
  • Example 3 Administration of D-threo-methylphenidate hydrochloride (rf-MPH) in the treatment of menopausal women having previously diagnosed Attention Deficit Disorder (ADD).
  • rf-MPH D-threo-methylphenidate hydrochloride

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/US2002/022039 2001-07-12 2002-07-11 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate Ceased WO2003005962A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR10-2004-7000312A KR20040029360A (ko) 2001-07-12 2002-07-11 Ｄ-트레오메틸페니데이트로 인지 장애 및 폐경기 장애를치료하는 방법
MXPA04000249A MXPA04000249A (es) 2001-07-12 2002-07-11 Metodos para tratamiento de trastornos cognitivos y menopausicos con d-treo-metilfenidato.
JP2003511771A JP2005520780A (ja) 2001-07-12 2002-07-11 Ｄ−ｔｈｒｅｏメチルフェニデートを用いる認識および閉経期の障害の治療方法
CA2453510A CA2453510C (en) 2001-07-12 2002-07-11 Treatment of fatigue and cognitive side effects associated with cancer, cancer treatments and menopause with d-threo-methyphenidate
EP02748129A EP1411943A4 (en) 2001-07-12 2002-07-11 METHODS FOR TREATING COGNITIVE DISORDERS OR MENOPAUSE DISORDERS BY D-THREO METHYLPHENIDATE
IL15931302A IL159313A0 (en) 2001-07-12 2002-07-11 Methods for treatment of cognitive and menopausal disorders with d-threo-methylphenidate
AU2002318302A AU2002318302B2 (en) 2001-07-12 2002-07-11 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
NZ530211A NZ530211A (en) 2001-07-12 2002-07-11 D-threo methylphenidate substantially free of the L-threo form to treat fatigue, neurobehavioral slowing and other cogitative disorders exacerbated by treatments associated with cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/903,803 2001-07-12
US09/903,803 US6486177B2 (en) 1995-12-04 2001-07-12 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate

Publications (2)

Publication Number Publication Date
WO2003005962A2 true WO2003005962A2 (en) 2003-01-23
WO2003005962A3 WO2003005962A3 (en) 2003-06-12

Family

ID=25418099

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/022039 Ceased WO2003005962A2 (en) 2001-07-12 2002-07-11 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate

Country Status (10)

Country Link
US (7) US6486177B2 (enExample)
EP (1) EP1411943A4 (enExample)
JP (1) JP2005520780A (enExample)
KR (1) KR20040029360A (enExample)
AU (1) AU2002318302B2 (enExample)
CA (1) CA2453510C (enExample)
IL (1) IL159313A0 (enExample)
MX (1) MXPA04000249A (enExample)
NZ (2) NZ565754A (enExample)
WO (1) WO2003005962A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006047330A3 (en) * 2004-10-22 2006-09-21 Mark Froimowitz Methylphenidate analogs and methods of use thereof
JP2007534763A (ja) * 2004-04-26 2007-11-29 セルジーン・コーポレーション 同時乱用の可能性を減少させる方法
JP2008523097A (ja) * 2004-12-09 2008-07-03 セルジーン・コーポレーション Ｄ−トレオメチルフェニデートを用いた治療
WO2012037093A1 (en) * 2010-09-13 2012-03-22 Tenera Therapeutics, Llc Compositions for treating cancer treatment - related fatigue

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2222713C (en) 1995-07-14 2003-04-22 Andrew John Mcglashan Richards Composition comprising d-threo-methylphenidate and another drug
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20020035139A1 (en) * 2000-06-20 2002-03-21 Herbst Arthur L. COX-2 inhibitors and the prevention of the side effects of radiation therapy
FR2823975B1 (fr) * 2001-04-27 2003-05-30 Sanofi Synthelabo Nouvelle utilisation de pyridoindolone
EP1680144B1 (en) * 2003-10-08 2011-10-05 Mallinckrodt LLC Methylphenidate solution and associated methods of administration and production
JP2008507552A (ja) * 2004-07-22 2008-03-13 ワイス 神経系障害および状態の治療方法
JP2008507550A (ja) * 2004-07-22 2008-03-13 ワイス 神経系障害及び状態の処置方法
KR20070045278A (ko) * 2004-07-22 2007-05-02 와이어쓰 신경계 질환 및 장애의 치료 방법
KR101318806B1 (ko) * 2005-01-20 2013-10-16 인스티튜트 포 몰리큘러 메디신, 인코포레이티드 메틸페니데이트 유도체 및 그 용도
US20060183773A1 (en) * 2005-01-20 2006-08-17 David Bar-Or Uses of methylphenidate derivatives
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
EP2018160B1 (en) 2006-03-16 2011-12-14 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
US9345558B2 (en) 2010-09-03 2016-05-24 Ormco Corporation Self-ligating orthodontic bracket and method of making same
US8287903B2 (en) 2011-02-15 2012-10-16 Tris Pharma Inc Orally effective methylphenidate extended release powder and aqueous suspension product
DK2755498T3 (en) * 2011-09-15 2018-05-22 Friulchem Spa COMPOSITION FOR ORAL ADMINISTRATION FOR ANIMALS AND PROCEDURE FOR OBTAINING
KR101312286B1 (ko) * 2012-11-26 2013-09-27 (주)비씨월드제약 즉시방출 및 조절방출 특성을 갖고 d-트레오-메틸페니데이트를 포함하는 약학 조성물
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US12458592B1 (en) 2017-09-24 2025-11-04 Tris Pharma, Inc. Extended release amphetamine tablets

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US105134A (en) * 1870-07-05 Thomas sheehan
US49205A (en) * 1865-08-01 Improvement in machines for hulling grain
US32335A (en) * 1861-05-14 Island
US19535A (en) * 1858-03-02 Improvement in sewing-machines
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
GB589625A (en) 1944-01-19 1947-06-25 Chem Ind Basel Manufacture of new pyridine and piperidine compounds
GB788226A (en) 1953-12-23 1957-12-23 Ciba Ltd Stereoisomers of ª‡-phenyl-ª‡-piperidyl-(2)-acetic acid and process of making same
US2838519A (en) * 1953-12-23 1958-06-10 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
US2957880A (en) 1953-12-23 1960-10-25 Ciba Pharm Prod Inc Process for the conversion of stereoisomers
GB878167A (en) 1958-11-17 1961-09-27 Ciba Ltd New acetic acid esters
SU466229A1 (ru) 1973-01-23 1975-04-05 Всесоюзный научно-исследовательский химико-фармацевтический институт им. С.Орджоникидзе Способ получени гидрохлорида метилового эфира трео- -фенил- (пиперидил-2)-уксусной кислоты
US4137300A (en) * 1976-08-20 1979-01-30 Ciba-Geigy Corporation Sustained action dosage forms
US4410700A (en) * 1980-07-03 1983-10-18 The United States Of America As Represented By The Department Of Health And Human Services Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution
DE3279999D1 (en) * 1981-09-30 1989-11-30 Nat Res Dev Compositions comprising encapsulated particles
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US4986987A (en) * 1986-05-09 1991-01-22 Alza Corporation Pulsed drug delivery
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5283193A (en) 1988-06-27 1994-02-01 Asahi Kasei Kogyo K.K. Process for producing optically active α-substituted organic acid and microorganism and enzyme used therefor
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5284769A (en) 1989-10-16 1994-02-08 Chiros Ltd. Process for preparing a single enantiomer of a lactam using lactamase
US5362755A (en) 1990-01-05 1994-11-08 Sepracor, Inc. Method for treating asthma using optically pure (R)-albuterol
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
US5158777A (en) * 1990-02-16 1992-10-27 E. R. Squibb & Sons, Inc. Captopril formulation providing increased duration of activity
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
DE69229881T2 (de) * 1991-10-04 1999-12-09 Yoshitomi Pharmaceutical Industries, Ltd. Tablette mit verzögerter freisetzung
DE69222006T2 (de) * 1991-10-30 1998-01-22 Glaxo Group Ltd Mehrschichtzusammensetzungen enthaltend Histamin- oder Serotonin- Antagonisten
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5331000A (en) 1992-03-09 1994-07-19 Sepracor Inc. Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen
US5299121A (en) * 1992-06-04 1994-03-29 Medscreen, Inc. Non-prescription drug medication screening system
US5512293A (en) * 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
DK0701443T4 (da) 1992-08-03 2000-12-18 Sepracor Inc Terfenadinmetabolitter og deres optisk rene isomerer til behandling af allergiske lidelser
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JP3091618B2 (ja) 1993-01-29 2000-09-25 四郎 小林 開環重合法および開環重合用酵素触媒
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5500227A (en) * 1993-11-23 1996-03-19 Euro-Celtique, S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale
GB9514451D0 (en) 1995-07-14 1995-09-13 Chiroscience Ltd Sustained-release formulation
WO1997003672A1 (en) 1995-07-14 1997-02-06 Chiroscience Limited THERAPEUTIC USE OF d-threo-METHYLPHENIDATE
CA2222713C (en) 1995-07-14 2003-04-22 Andrew John Mcglashan Richards Composition comprising d-threo-methylphenidate and another drug
US6355656B1 (en) * 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5908850A (en) 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5733756A (en) 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6242464B1 (en) * 1996-01-22 2001-06-05 Chiroscience Limited Single isomer methylphenidate and resolution process
MX9805870A (enExample) 1996-01-22 1999-01-31
HUP9901658A3 (en) 1996-02-02 1999-12-28 Medeva Europ Ltd Process for the preparation of d-threo-(r,r)-methyl phenidate and recycling of undesired enantiomers by epimerisation
GB9604943D0 (en) * 1996-03-08 1996-05-08 Chiroscience Ltd Resolution
CA2243542C (en) 1996-03-08 2003-02-18 Medeva Europe Limited Resolution of threo-methylphenidate
GB9606417D0 (en) * 1996-03-27 1996-06-05 Chiroscience Ltd Asymmetric cyclisation
CN1182839C (zh) 1996-11-25 2005-01-05 阿尔萨公司 递增剂量的剂型
HUP0001604A3 (en) 1996-12-13 2003-03-28 Medeva Europ Ltd The preparation of an enantiomerically-enriched threo-methylphenidate
GB9700912D0 (en) * 1997-01-17 1997-03-05 Chiroscience Ltd Resolution
US5965734A (en) * 1997-01-31 1999-10-12 Celgene Corporation Processes and intermediates for preparing 2-substituted piperidine stereoisomers
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US5936091A (en) * 1997-05-22 1999-08-10 Celgene Corporation Processes and intermediates for resolving piperidyl acetamide stereoisomers
HU230454B1 (hu) * 1998-11-02 2016-07-28 Alkermes Pharma Ireland Limited Metilfenidátot tartalmazó módosított felszabadulású sokszemcsés készítmény
US6127385A (en) * 1999-03-04 2000-10-03 Pharmaquest Limited Method of treating depression using l-threo-methylphenidate
US6395752B1 (en) * 1999-03-04 2002-05-28 Pharmaquest Limited Method of treating depression using 1-threo-methylphenidate
GB9913458D0 (en) 1999-06-09 1999-08-11 Medeva Europ Ltd The therapeutic use of d-threo-methylphenidate
ATE252903T1 (de) 1999-12-17 2003-11-15 Celltech Pharma Europ Ltd Arzneimittel zur behandlung konvulsivischer zustände
US6221883B1 (en) * 2000-04-12 2001-04-24 Ross Baldessarini Method of dopamine inhibition using l-threo-methylphenidate
US20020132793A1 (en) * 2000-08-28 2002-09-19 Mel Epstein Use of methylphenidate compounds to enhance memory
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
US6359139B1 (en) * 2000-11-07 2002-03-19 Celgene Corporation Methods for production of piperidyl acetamide stereoisomers

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534763A (ja) * 2004-04-26 2007-11-29 セルジーン・コーポレーション 同時乱用の可能性を減少させる方法
WO2006047330A3 (en) * 2004-10-22 2006-09-21 Mark Froimowitz Methylphenidate analogs and methods of use thereof
JP2008523097A (ja) * 2004-12-09 2008-07-03 セルジーン・コーポレーション Ｄ−トレオメチルフェニデートを用いた治療
WO2012037093A1 (en) * 2010-09-13 2012-03-22 Tenera Therapeutics, Llc Compositions for treating cancer treatment - related fatigue

Also Published As

Publication number Publication date
MXPA04000249A (es) 2004-05-04
US20060183774A1 (en) 2006-08-17
US20110257227A1 (en) 2011-10-20
US20100093797A1 (en) 2010-04-15
CA2453510C (en) 2012-03-20
CA2453510A1 (en) 2003-01-23
US20130053414A1 (en) 2013-02-28
NZ565754A (en) 2009-05-31
NZ530211A (en) 2008-04-30
US20020022640A1 (en) 2002-02-21
IL159313A0 (en) 2004-06-01
AU2002318302B2 (en) 2007-03-15
JP2005520780A (ja) 2005-07-14
US6486177B2 (en) 2002-11-26
US20020198234A1 (en) 2002-12-26
EP1411943A4 (en) 2005-09-28
WO2003005962A3 (en) 2003-06-12
US7115631B2 (en) 2006-10-03
KR20040029360A (ko) 2004-04-06
EP1411943A2 (en) 2004-04-28
AU2002318302C1 (en) 2003-01-29
US20040204456A1 (en) 2004-10-14

Similar Documents

Publication Publication Date Title
AU2002318302C1 (en) Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
AU2002318302A1 (en) Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
AU738521B2 (en) Chronic, bolus administration of D-threo methylphenidate
US5908850A (en) Method of treating attention deficit disorders with d-threo methylphenidate
US20100104621A1 (en) Treating adhd and other diseases involving inflammation
CA2799087A1 (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
US6774131B1 (en) Remedies for endothelin-induced diseases
EP1490057A1 (en) Method for treating cognitive disorders
US20050277626A1 (en) Methods and compositions for treatment of nicotine dependence and dementias
EP0545805A1 (fr) Utilisation de la D-fenfluramine et de dérivés de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-résistants
JP2008523097A (ja) Ｄ−トレオメチルフェニデートを用いた治療
Tiseo et al. P. 4.023 The pharmacokinetics and pharmacodynamics of (R)-and (S)-Warfarin are unaffected by co-administration of donepezil
HK1111361A (en) Chronic, bolus administration of d-treo methylphenidate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG US

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 159313

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 530211

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002318302

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 028133498

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003511771

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/000249

Country of ref document: MX

Ref document number: 1020047000312

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2453510

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002748129

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002748129

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2002318302

Country of ref document: AU